Parametric Portfolio Associates’s Vir Biotechnology VIR Stock Holding History

Parametric Portfolio Associates’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$5.9M	Sell	229,301 -101,262	-31%	-$3M	﹤0.01%	1737
2021 Q4	$13.8M	Buy	330,563 +191,458	+138%	+$7.5M	0.01%	1173
2021 Q3	$6.05M	Sell	139,105 -752	-0.5%	-$32.6K	﹤0.01%	1703
2021 Q2	$6.61M	Buy	139,857 +38,141	+37%	+$1.73M	﹤0.01%	1664
2021 Q1	$5.21M	Buy	101,716 +59,857	+143%	+$3.23M	﹤0.01%	2140
2020 Q4	$1.12M	Buy	41,859 +2,160	+5%	+$70.2K	﹤0.01%	2984
2020 Q3	$1.36M	Sell	39,699 -31,261	-44%	-$1.35M	﹤0.01%	2723
2020 Q2	$2.91M	Buy	+70,960	New	+$2.38M	﹤0.01%	2252

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Parametric Portfolio Associates's VIR Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Vir Biotechnology (VIR) stake by 31% in Q1 2022, selling an estimated $3M and leaving 229,301 shares worth $5.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1737.

Parametric Portfolio Associates first reported a position in VIR in Q2 2020 and has held it in 8 quarters since. The position peaked at $13.8M in Q4 2021. 204 funds tracked by Wall St. Rank hold VIR as of Q1 2022.

Parametric Portfolio Associates held 229,301 shares of Vir Biotechnology worth $5.9M as of Q1 2022.
Parametric Portfolio Associates sold 101,262 Vir Biotechnology shares in Q1 2022, an estimated $3M.
Vir Biotechnology made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1737 holding.
Parametric Portfolio Associates first reported a position in Vir Biotechnology in Q2 2020 and has held it in 8 quarters since.
Parametric Portfolio Associates's Vir Biotechnology position peaked at $13.8M in Q4 2021.
204 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.